SLC5A2 and chronic kidney disease: Moreover, we do not include the new treatments, such as glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors, which reduce the risk of CKD progression and mortality among persons with T2DM (8).